REVIEW Linifanib (A 741439; A-741439; A741439; ABT-869; ABT869; RG3635) is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers. The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors and is a multitargeted tyrosine kinase receptor inhibitor that suppresses FLT3 signaling. It is in phase III development for liver cancer and phase II development for non-small cell lung cancer, breast cancer, and colorectal cancer in the US, the EU and other areas of the world. (PMID:20698720); Recent research also indicates that Linifanib inhibits proliferation and induces apoptosis in AML patient cells via reduction of AKT and GSK3beta phosphorylation and maybe influential in AML therapy. (PMID:21471285)
![[796967-16-3] Linifanib AKSci SYN1002](/images/header-logo.png "[796967-16-3] Linifanib AKSci SYN1002"){kind=logo}
Add to Favorites 
Delete from Favorites 
